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Derivatives of vitamin B12 (cobalamin) are essential cofactors for enzymes required in intermediary metabolism. Defects in cobalamin
metabolism lead to disorders characterized by the accumulation of methylmalonic acid and/or homocysteine in blood and urine. The
most common inborn error of cobalamin metabolism, combined methylmalonic acidemia and hyperhomocysteinemia, cblC type, is
caused by mutations in MMACHC. However, several individuals with presumed cblC based on cellular and biochemical analysis do not
have mutations inMMACHC. We used exome sequencing to identify the genetic basis of an X-linked form of combined methylmalonic
acidemia and hyperhomocysteinemia, designated cblX. A missense mutation in a global transcriptional coregulator, HCFC1, was identi-
fied in the index case. Additionalmale subjects were ascertained through two international diagnostic laboratories, and 13/17 had one of
five distinctmissensemutations affecting three highly conserved amino acids within theHCFC1 kelch domain. A commonphenotype of
severe neurological symptoms including intractable epilepsy and profound neurocognitive impairment, alongwith variable biochemical
manifestations, was observed in all affected subjects compared to individuals with early-onset cblC. The severe reduction in MMACHC
mRNAandproteinwithin subject fibroblast lines suggested a role forHCFC1 in transcriptional regulationofMMACHC,whichwas further
supported by the identification of consensus HCFC1 binding sites in MMACHC. Furthermore, siRNA-mediated knockdown of HCFC1
expression resulted in the coordinate downregulation of MMACHC mRNA. This X-linked disorder demonstrates a distinct disease
mechanism by which transcriptional dysregulation leads to an inborn error of metabolism with a complex clinical phenotype.Introduction
Cobalamin-derived cofactors, 50-adenosylcobalamin (Ado-
Cbl) and methylcobalamin (Me-Cbl), are essential for the
activity of methylmalonyl-CoA mutase (MUT [ENZYME
EC 5.4.99.2]) and methionine synthase (MTR [ENZYME
EC 2.1.1.13]), respectively. MUT functions in the catabo-
lism of branched-chain amino acids and odd-chain fatty
acids into the Krebs cycle, and MTR catalyzes the remethy-
lation of homocysteine to methionine. Mutations in MUT
(MIM 609058) or MTR (MIM 156570) or defects in either
the intracellular transport of cobalamin or the synthesis
of the active enzymatic cofactors result in one of nine
distinct inborn errors of metabolism, historically desig-
nated by the cellular complementation class (mut, cblA–
cblG, or cblJ).1 The disorders that affect both the synthesis
and the transport of 50-Ado-Cbl and Me-Cbl (cblC [MIM
277400]), cblD combined [MIM 277410], cblF [MIM
277380], and cblJ [MIM 614857]) share the characteristic
biochemical findings of combined methylmalonic acide-
mia and hyperhomocysteinemia.
Combined methylmalonic acidemia and hyperhomo-
cysteinemia, cblC type, one of the first recognized and
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clinical phenotype of cblC is diverse and can feature neuro-
logic, renal, cardiac, hematologic, and ophthalmologic
manifestations.3–5 Although the clinical phenotypes of
cblD combined, cblF, and cblJ defects are not as well delin-
eated, most reported cases have been phenotypically
similar to cblC.6–8 The genes associated with these disor-
ders have been discovered.6–9 However, several individuals
who have a cellular, but not molecular, diagnosis of cblC
still exist,2,9 suggesting genetic heterogeneity within this
complementation group. MMACHC sequence analysis did
not identify causative mutations in 14/2049 or 3/1182 re-
ported individuals with biochemically confirmed cblC
deficiency.
Here, we describe the identification of an X-linked form
of combinedmethylmalonic acidemia and hyperhomocys-
teinemia, designated cblX. Exome sequencing of a male
subject initially diagnosed with cblC by complementation
analysis but who had nomutations inMMACHC identified
a mutation in HCFC1 (MIM 300019), a coregulator of the
zinc-finger transcription factor THAP11 (also known as
RONIN).10,11 Sanger sequencing of HFCF1 in 17 additional
male subjects revealed that 13 harbored one of five patho-
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further implicated HCFC1 in transcriptional regulation of
MMACHC.Subjects and Methods
Human Subjects
All human subject samples used in this study were collected after
informed consent was obtained. Subject 1 and his parents were
enrolled into a research protocol (COMIRB no. 07-0386) approved
by the institutional review board at the University of Colorado,
School of Medicine. Subject 1, subject 11, and their parents were
enrolled in National Institutes of Health study ‘‘Clinical and Basic
Investigations of Methylmalonic Acidemia and Related Disorders’’
(clinicaltrials.gov identifier NCT00078078) in compliance with
the Helsinki Declaration and provided informed consent. The
studies at McGill University Health Centre (Montreal) and Univer-
sity Children’s Hospital (Zurich) were approved by their respective
ethics committees. Genomic DNA was obtained from either
peripheral-blood lymphocytes or cultured skin fibroblasts.Whole-Exome Sequencing
Whole-exome sequencing (WES) on subject 1 and his parents was
performed with Nimblegen SeqCap EZ Exome v.2.0 and was fol-
lowed by sequencing on an Illumina HiSeq 2000. Approximately
50 million 90 bp paired-end reads (>503) were obtained.
Sequence reads were first mapped to the human reference genome
(hg19 assembly, UCSC Genome Browser) with the Burrows-
Wheeler Aligner12 and then visualized with the Integrative Geno-
mics Viewer.13 The utilities in SAMtools14 were used for variant
calling, and variants were annotated with SeattleSeq. Further
filtering and testing of the inheritancemodel were done with tools
in Galaxy.15 Single-nucleotide variants (SNVs) were filtered for re-
taining calls that met the following criteria: SNP and consensus
scores >50, read coverage >8, and >25% of the reads containing
the variant call. Bases with a PHRED-scaled score <20 were
removed from the analysis. For homozygous and hemizygous
variant calls, >80% reads were required to contain the variant,
whereas for heterozygous variant calls, the number of reads con-
taining the variant call ranged between 25% and 80%. Indels
< 50 bp were filtered on the basis of similar criteria, except that
the SNP and consensus scores were required to be >100. Variants
found in segmental duplications or simple- or low-complexity re-
peats were removed because of the higher likelihood of mapping
errors. Sequence data from parental samples were used as an addi-
tional filter for confirmation of variant calls in subject 1. The
filtering criteria for variant calling in parental data were less strin-
gent than those in subject 1 so that erroneous classification of var-
iants as unique to subject 1 could be minimized. Thus, the criteria
for parental data included SNP score > 5 for SNVs and SNP score
> 10 for indels and required that at least two reads contain the
variant call. Variants were filtered against dbSNP build 135 and
1000 Genomes (November 23, 2010 release). The sequence data
from the family was then used for testing for causal variants under
different inheritance models, including a de novo mutation in a
dominant model and compound-heterozygous, homozygous,
and X-linked hemizygous mutations in recessive models.Sanger Sequencing
Variants identified in HCFC1 and TTN (MIM 188840) were further
validated by Sanger sequencing in subject 1 and his parents.The AmericanMutations detected in HCFC1 and TTN were named with the
use of RefSeq cDNA accession numbers NM_005334.2 and
NM_133378.4, respectively. Primers were designed to amplify
and sequence the 26 coding exons of HCFC1 in the 17 additional
subjects and available parents (Table S1, available online).
Genomic DNA (100 ng) was amplified with the following PCR
conditions: Promega GoTaq Hot Start kit with 13 Master Mix
and 400 nM of each primer. PCR began with an initial cycle at
95C for 3 min and 30 subsequent cycles of 94C for 30 s, 60C
for 30 s, and 72C for 1 min and finished with an extension at
72C for 5 min. Amplified PCR products were sequenced with
the PCR primers as sequencing primers on an ABI PRISM 3730xl
by a commercial sequencing facility.
Protein Alignment
HCFC1 sequences in human (RefSeq NP_005325.2), chimpanzee
(RefSeq XP_521330.3), mouse (RefSeq NP_032250.2), rat (RefSeq
NP_001132979.1), frog (RefSeq XP_002937269.1), and two zebra-
fish paralogs (RefSeqNP_001122009.1 andNP_001038529.1) were
aligned with ClustalW.16
Protein Modeling
Predicted models of the wild-type and altered HCFC1 (UniProtKB
P51610) kelch domain (amino acids 42–342) were created by
Modeller17 with human KLHL12 (Protein Data Bank ID 2VPJ) as
a modeling template. KLHL12 was chosen by CPHmodels18
because it had an available proteinmodel with the highest homol-
ogy with the HCFC1 kelch domain. The resulting structures were
visualized with Chimera.19
HCFC1 and THAP11 Binding Sites
Binding regions of HCFC1 and THAP11 were obtained from chro-
matin immunoprecipitation sequencing (ChIP-seq) data in mouse
embryonic stem cells.10 Mouse genomic coordinates from the
mm8 assembly of the UCSC Genome Browser were converted to
the orthologous human hg19 assembly with the LiftOver tool
from the UCSC Genome Browser.20 A highly conserved 15 bp
(50-CTGGGARWTGTAGTY-30) THAP11 binding motif10 was iden-
tified by fuzznuc21 in the human genome. A maximum of 2 bp
mismatch was allowed.
Analysis of RNA Expression
For quantitative evaluation of gene expression, total RNA was iso-
lated from human fibroblasts and reverse transcribed. The two
control samples used were from healthy individuals with no
known biochemical or neurological phenotypes. The Promega
GoScript reverse-transcription system was used for converting
RNA to cDNA with random primers. Assays for quantitative PCR
(qPCR) were designed with the Roche Universal ProbeLibrary
DesignCenter, and RocheUniversal Probes and FastStart Universal
Probe Master Mix with Rox were used. The Roche Universal
ProbeLibrary Human ACTB (b-actin) Gene Assay was used as an
endogenous control (catalog no. 05046165001). Primers (Table
S1) were synthesized by Integrated DNA Technologies. Primer
pairs that showed an amplification efficiency within 5 10% of
each other and a coefficient of correlation between 0.95 and 1.0
were used for quantification. ABI 7500 Software version 2.0.5
was used to calculate the relative expression levels with the
DDCT method. The reactions were all carried out in technical
triplicates. The experiment was also repeated in three biological
replicates. Error bars represent the SEM of relative expressionJournal of Human Genetics 93, 506–514, September 5, 2013 507
levels. Statistical significance was calculated with a two-tailed
t test.
Immunoblot Analysis
Control human dermal fibroblasts (C-013-5C) were obtained from
Life Technologies. Human fibroblasts were grown to ~95% conflu-
ence in 10 cm plates and lysed in T-PER containing a protease-
inhibitor cocktail (Thermo Fisher Scientific). Crude lysates were
clarified by centrifugation at 13,000 rpm for 10 min at 4C.
Seventy-five micrograms of lysate was analyzed by immunoblots
with a rabbit polyclonal MMACHC (ab96195; Abcam) antibody
at a dilution of 1:1,000 or rabbit polyclonal HCFC1 antibody
(A301-400A; Bethyl Laboratories) at a dilution of 1:2,000. The
blot was stripped with Restore Western Blot Stripping Buffer
(Thermo Fisher Scientific) and reprobed with a rabbit polyclonal
b-actin antibody at a dilution of 1:3,000 as a loading control.
Secondary antibody was visualized by chemiluminescence detec-
tion (Thermo Fisher Scientific). Immunoblots for HCFC1 siRNA
knockdown experiments were performed on cell lysates obtained
from human embryonic kidney 293 (HEK293) cells (American
Type Culture Collection) treated with either HCFC1 siRNA or
scrambled siRNA in three biological replicates. Cells were har-
vested for immunoblotting 4 days after transfection. The anti-
bodies used for immunoblot analysis of HCFC1 and b-actin were
the same as above.
HCFC1 siRNA Knockdown
HEK293 cells were transfected with Trilencer-27 siRNA duplexes
(Origene) with the use of the siTran transfection reagent and incu-
bated for 48 hr. RNA was isolated from HCFC1 siRNA-treated cells
and scrambled-siRNA-treated control cells with the RNeasy Micro
Kit (QIAGEN). Total RNA was quantitated in each individual sam-
ple, and 1 mg of total RNA was used for producing cDNA with
random hexamer primers with the GoScript Reverse Transcription
System (Promega) according to the manufacturer’s instructions.
Quantitative PCRwas performed as described above. The reactions
were all carried out in technical triplicates. The experiment was
also repeated in three biological replicates. Error bars represent
the SEM of relative expression levels. Statistical significance was
calculated with a two-tailed t test.
MMA Production by Cultured cblX Fibroblasts
A modified chemical-stimulation study was performed as
described previously.22 Six-well tissue-culture plates were seeded
at a density of 2 3 105 or 5 3 105 cells per well in high glucose
(4 g/l) DMEM supplemented with 10% fetal bovine serum, peni-
cillin streptomycin, L-glutamine, and sodium pyruvate. The next
day, the DMEM growth medium was removed and replaced with
1 ml of DMEM growth medium containing sodium propionate
(10 mM) or sodium propionate (10 mM) plus hydroxocobalamin
(1 mg/ml). After 72 hr, the medium was collected for gas chroma-
tography–mass spectrometry analysis of MMA and measured in
triplicate. Cell viability was determined by visual inspection and
noted to be equal in all groups.Results
Clinical Data
The clinical features of subjects are shown in Table 1. A
common phenotype of severe neurological symptoms,508 The American Journal of Human Genetics 93, 506–514, Septembwhich primarily include intractable epilepsy and neuro-
cognitive impairment, was observed in all affected males
(Table 1). Disease onset was either in the prenatal period
(n¼ 3) or in early infancy (n¼ 11), and severe neurological
manifestations were present in all subjects. Seizures (n ¼
12), profound developmental delay (n¼ 11), microcephaly
(n ¼ 7), movement disorders (n ¼ 4), and a history of
maternal male infant deaths (n ¼ 3) were reported.
Biochemical perturbations included hyperhomocysteine-
mia, methylmalonic acidemia, and increased propionyl-
carnitine (Table 1 and Table S2). Laboratory values were
more variable than seen in individuals with early-onset
cblC4 (Figure 1) given that five cblX subjects had normal
plasma total homocysteine. Cellular biochemical studies
were performed in all subjects and revealed diminished
1-[14C]-propionate and 5-[14C]-methyl-THF incorporation
(which improved with hydroxocobalamin supplementa-
tion), impaired synthesis of Ado-Cbl and Me-Cbl (Table
S2), and failure to complement respective cblC cell lines.
WES
We selected one male subject (subject 1) with presumed
cblC for WES analysis because of his atypical neurological
phenotype, which included a gyral cortical malformation
that required surgical resection. We first filtered out com-
mon variants present in dbSNP and 1000 Genomes and
focused on nonsynonymous coding variants, coding in-
dels, and variants affecting splice sites, resulting in 161
rare variants that were considered for further analysis
(Table S3). Parental WES data were used for identifying
possible pathogenic variants under various inheritance
models, including dominant (de novo mutations) and
recessive (compound-heterozygous, homozygous, and
X-linked hemizygous mutations) models.
Under the recessive model, we identified two candidate
genes with potentially pathogenic mutations. The first,
TTN, encodes Titin, a giant protein involved in the
assembly of cardiac and skeletal muscle. Subject 1 had
compound-heterozygous missense changes in TTN:
c.61634G>A (p.Arg20545Gln) inherited from his mother
and c.77236G>A (p.Val25746Ile) inherited from his father.
The only known function of TTN inmuscle assemblymade
it unlikely to play a role in disease etiology. The second
candidate, HCFC1 on chromosome X, had a nonsynony-
mous,missense variant in exon 3, c.344C>T (p.Ala115Val).
Sanger sequencing validated the variant in subject 1 and
his unaffected carrier mother. This mutation was not
found in the subject’s maternal grandparents, suggesting
that the mutation might have originated de novo in his
mother (Figure S1A). The pleiotropic function of HCFC1
coupled with the recent description of an X-linked form
of mental retardation (MRX3 [MIM 309541]) caused by
its altered expression prompted further investigations.23
HCFC1 Mutation Screening
Seventeen additional males, the majority of whom had
been diagnosed with cblC deficiency by cellular studieser 5, 2013
Table 1. Clinical and Biochemical Features of Male Subjects with HCFC1 Variants
Subject Age of Onset Clinical Symptoms
Genetic Testing
(Negative) HCFC1 Variant
Plasma tHcya
(mmol/l)
Serum MMAb
(mmol/l)
Urine MMAc
(mmol/mol
creatinine)
1 4 months severe developmental delay, infantile spasms with hypsarrythmia, gyral cortical
malformation, microcephaly, chorea, undescended testes, megacolon
MMACHC c.344C>Td (p.Ala115Val) 141 21.5 ND
2 4 months severe developmental delay, intractable epilepsy, choreoathetosis,
microcephaly, FTT
MMACHC c.344C>T (p.Ala115Val) ND ND 650
3 prenatal severe developmental delay, neonatal epilepsy, choreoathetosis, congenital
microcephaly, FTT
MMACHC c.344C>T (p.Ala115Val) ND ND elevated
4 <3 months infantile spasms with hypsarrythmia, absent development MMACHC c.344C>T (p.Ala115Val) 5 ND 201
5 2 months severe developmental delay, epilepsy, choreoathetosis, neutropenia MMACHC c.344C>T (p.Ala115Val) WNL ND 626
6 prenatal severe developmental delay, infantile spasms with hypsarrythmia,
microcephaly, IUGR
MMACHC c.344C>T (p.Ala115Val) ND 22.7 192
7 4 months epilepsy, hypotonia MMACHC c.344C>T (p.Ala115Val) 118 11.6 ND
8 <3 months severe developmental delay, intractable epilepsy, hypospadias MMACHC c.344C>T (p.Ala115Val) 80 ND elevated
9 <3 months severe developmental delay, epilepsy, no eye contact, muscular hypotonia,
microcephaly
MMACHC c.344C>T (p.Ala115Val) 61 5.5 ND
10 2 weeks acute neurologic and metabolic decompensation, ketoacidosis with
hyperammonemia, microcephaly, abnormal EEG, death in infancy
MMACHC c.343G>A (p.Ala115Thr) ND elevated elevated
11 5 months severe developmental delay, intractable epilepsy, choreoathetosis, FTT,
ballismus
MMADHC, MMACHC c.218C>Te (p.Ala73Val) 9 5.7 127
12 9 weeks severe developmental delay, epilepsy, muscular hypotonia, generalized
disturbance and delay of myelination on MRI at age 8 years
MMACHC c.218C>T (p.Ala73Val) 13 ND 329
13 5 weeks severe developmental delay, epilepsy, FTT MMACHC c.217G>A (p.Ala73Thr) WNL ND elevated
14 prenatal seizures, blindness, hearing impairment, slight dysmorphia, congenital
microcephaly, IUGR, FTT
MMACHC c.202C>G (p.Gln68Glu) 87 23.0 elevated
Abbreviations are as follows: FTT, failure to thrive; IUGR, intrauterine growth retardation; ND, not determined; and WNL, within normal limits.
aNormal is <13 mmol/l.
bNormal is <0.4 mmol/l.
cNormal is undetectable.
dMother was found to carry a de novo variant.
eDe novo variant.
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Figure 1. Metabolite Measurements in cblX Subjects Compared to Treated, Early-Onset cblC Subjects
Plasma total homocysteine (tHcy) and serum and urine methylmalonic acid (MMA) were measured in cblX subjects (single measure-
ments) and 23 subjects with early-onset cblC deficiency (1–13 measurements per subject). In cases where multiple measurements
were available for the same subject, the mean of all readings was used. n ¼ the total number of subjects in each group.
(A) There was no statically significant difference in plasma tHcy measurements between cblC subjects and cblX subjects (cblC, 60.635
4.88 mM; cblX, 64.255 18.30 mM [mean5 SEM]). Normal levels of plasma tHcy are<13 mM. Triangles indicate two subjects with report-
edly normal tHcy (no concentration was provided to the referring diagnostic laboratory).
(B) There was no significant difference in serum MMA measurements between cblC subjects and cblX subjects (cblC, 11.575 2.99 mM;
cblX, 15.005 3.43 mM [mean5 SEM]). Normal levels of serum MMA are <0.4 mM.
(C) cblX subjects had higher urine MMA (t test p < 0.001) than did cblC subjects (cblC, 96.52 5 23.89 mmol/mol creatinine; cblX,
354.205 93.70 mmol/mol creatinine [mean5 SEM]). Normal levels of urine MMA are <4 mmol/mol creatinine.but who likewise did not have mutations in MMACHC
(Table 1), were identified through a retrospective review
of laboratory and clinical data from two international
referral centers. Sanger sequencing of the coding exons
and splice sites of HCFC1 identified one of five distinct
pathogenic missense mutations in 13/17 subjects:
three in exon 2 (c.202C>G [p.Gln68Glu], c.217G>A
[p.Ala73Thr], and c.218C>T [p.Ala73Val]) and two
in exon 3 (c.343G>A [p.Ala115Thr] and c.344C>T
[p.Ala115Val]). The missense changes affect three highly
conserved amino acids: Gln68, Ala73, and Ala115 (Fig-
ure 2). The mutation present in the index case, c.344C>T
(p.Ala115Val), was the most frequent and was present in
nine of the subjects.
Parental samples were only available for subject 1, whose
mother was a carrier, and subject 11, whose parents were
both negative for the c.218C>T (p.Ala73Val) change (the
fact that subject 11’s parents were negative for the muta-
tion suggests that it arose de novo). Sanger sequencing of
HCFC1 in 100 normal controls (50 individuals of European
descent and 50 African Americans; Human Variation
Panel, Coriell Institute) identified a single African Amer-
ican female carrier (NA17132) of the c.344C>T mutation.
We concurrently analyzed exome data from 7,597 controls
(6,503 from the National Heart, Lung, and Blood Institute
[NHLBI] Exome Sequencing Project Exome Variant Server
and 1,094 from 1000 Genomes) and did not discover any
of the variants detected in our cohort.
HCFC1 contains a kelch domain with five kelch motifs,
fibronectin-like domains, and an HCF-proteolysis domain
with sixHCF repeats24 (Figure 2). The fivemutations identi-
fied in the cblX individuals affect Gln68, Ala73, and Ala115
within adjacent kelchmotifs (Figure 2) and are predicted to
be deleterious (Table S4). Furthermore, the predicted three-
dimensional structure of wild-type HCFC1 (Figure S2)
places Gln68, Ala73, and Ala115 in close proximity to
each other. Interestingly, the introduction of the Ala73510 The American Journal of Human Genetics 93, 506–514, Septemband Ala115 substitutions leads to a conformational change
in the HCFC1 structure predicted by Modeller17 (Figures
S2B, S2D, and S2E), suggesting that the observed missense
mutations could alter the protein structure of HCFC1.
Binding Sites of the THAP11-HCFC1 Complex
ChIP-seq studies in mouse embryonic stem cells10 have
previously shown that the THAP11-HCFC1 complex binds
consensus-sequence motifs in genes encoding enzymes of
cobalamin metabolism, e.g., MMACHC, MTR, and ABCD4
(MIM 603214), as well as SUCLG1 (MIM 611224). SUCLG1
encodes a Krebs-cycle enzyme, and mutations in this gene
cause a severe form of isolated methylmalonic aciduria.25
We identified orthologous, conserved binding motifs for
the THAP11-HCFC1 complex in human MMACHC, MTR,
ABCD4, and SUCLG1 (Figure S3), suggesting that the
expression of human MMACHC and possibly other cobal-
amin metabolism enzymes is regulated by the THAP11-
HCFC1 complex.
Analysis of RNA and Protein Expression
To further characterize the functional consequences of
the observed HCFC1 mutations in vitro, we examined
the expression of various enzymatic targets—MMACHC,
MMADHC, MTR, SUCLG1, and ABCD4—in skin fibro-
blasts from two cblX individuals (subjects 1 and 11) by
using qPCR and immunoblots (Figure 3). Whereas ex-
pression levels of MMADHC, MTR, SUCLG1 and ABCD4
in subjects 1 and 11 were similar to those in two
control fibroblast lines, MMACHC mRNA and MMACHC
expression levels (Figures 3A and 3B) were severely reduced
in the affected individuals. The expression levels of HCFC1
mRNA (Figure 3A) and HCFC1 (Figure 3C and Figure S4)
were similar in the fibroblasts of control and affected
individuals, showing that the missense mutations in
HCFC1 do not affect its expression but apparently inhibit
its function in the transcriptional activation of MMACHC.er 5, 2013
Figure 2. Pathogenic Variants of HCFC1
in cblX
(A) The top panel shows the 26 exons of
HCFC1 as gray boxes. The bottom panel
shows the predicted HCFC1 domains,
including the kelch domain (kelch motifs
K1–K5), Fn3 (fibronectin type 3), the basic
domain, HCF-proteolysis repeats (HCF-
pro; represented as triangles), the acidic
domain, and NLS (nuclear localization
signal) domains (adapted from Wilson
et al.24). The HCFC1 mutations are clus-
tered within exon 2 and 3 of the cDNA,
corresponding to the first (K1) and second
(K2) kelch motifs, respectively, in HCFC1.
(B) Comparative analysis of HCFC1
from multiple species demonstrated that
Gln68, Ala73, and Ala115 (highlighted
in red) are evolutionarily conserved
throughout vertebrates.Functional Analysis of HCFC1 by siRNA Knockdown
In order to further demonstrate the regulatory role of
HCFC1 in MMACHC transcription, we performed siRNA
knockdown of HCFC1 in HEK293 cells. The reduction in
HCFC1 expression resulted in the coordinate downregula-
tion of MMACHC in siRNA-treated cells, but not in un-
treated control cells (Figure 4). This suggests that HCFC1
regulates the expression ofMMACHC, explaining the lower
levels of MMACHC expression in the fibroblasts of affected
individuals (Figure 3). This is further supported by the
observation that fibroblasts from cblX individuals pro-
duced excessive methylmalonate as a result of reduced
MMACHC expression, which normalized after cobalamin
supplementation (Figure S5).Discussion
WES of the index case and his unaffected parents allowed
us to discover the mutation underlying his complex clin-
ical phenotype, which included an apparent cblC defi-
ciency combined with severe neurological phenotypes.
HCFC1, unlike other genes associated with cobalamin dis-
orders, does not encode an enzyme in the cobalamin
pathway. It is in fact a predicted transcriptional coregulator
of enzymes involved in cobalamin metabolism, including
that encoded by MMACHC, mutations in which are
responsible for cblC deficiency.2 The location of HCFC1
on human chromosome X, combined with the existence
of several males with apparent cblC deficiency and no
MMACHCmutations,2,9 led us to predict that this disorder
might represent an X-linked disorder affecting males.
Indeed, we identified HCFC1 mutations in 13/17 addi-
tional male subjects with biochemical and cellular findings
that were similar to the index case, leading us to designate
this cobalamin disorder cblX.
All of the mutations discovered in our cohort affect
conserved amino acids in two of the five kelch motifs
within the HCFC1 kelch domain. Kelch domains are typi-The Americancally repetitive antiparallel b sheets and are known to
mediate protein-protein interactions, catalytic activity,
and transportation.26,27 The HCFC1 kelch domain recog-
nizes a conserved HCFC1 binding motif,28,29 which is
important for protein-protein interaction with its tran-
scriptional-regulation partners.30–33 HCFC1 is known to
interact with diverse proteins to regulate a variety of pro-
cesses, including the cell cycle, proliferation, and transcrip-
tion,30,34,35 and exerts control on targets through THAPs,
specifically THAP11.10,11 Thus, mutations that interfere
with the interaction between HCFC1 and its transcrip-
tional-regulation partners are likely to affect the expression
of a wide range of downstream effectors. It is noteworthy
that HCFC1 interacts with many other transcription fac-
tors, such as E2Fs, MLLs, CREB, BAP1, and SETD1A,
through the kelch domain and subsequently has an exten-
sive effect on transcription activities.29,30,32,34 In a recent
study, the HCFC1 complex was shown to be bound to
~5,400 (24%) promoters of the human transcriptome,
including the THAP11 promoter.36
The most obvious question that we needed to address
next was how mutations in HCFC1 might affect cobal-
amin metabolism and the apparent cblC deficiency
observed in the cblX individuals. We first demonstrated
that predicted binding motifs for the THAP11-HCFC1
complex exist in the regions flanking human MMACHC,
as well as other genes encoding components of the
cobalamin pathway. We then showed that expression
levels of both MMACHC mRNA and MMACHC were
severely reduced in skin fibroblasts from cblX individuals.
Furthermore, siRNA knockdown of HCFC1 expression
in HEK293 cells led to coordinate downregulation of
MMACHC transcription. Thus, our data strongly sup-
port a model in which the THAP11-HCFC1 complex
controls the expression of MMACHC. Mutations that
affect binding of HCFC1 and THAP11 could then lead
to the cellular and biochemical phenotype of cblC defi-
ciency as a result of a reduction in the expression of
MMACHC.Journal of Human Genetics 93, 506–514, September 5, 2013 511
Figure 3. Expression Analysis
(A) qPCR analysis of mRNA expression.
MMACHC expression was either com-
pletely lost or reduced by ~76% in fibro-
blasts derived from subjects 1 and 11,
respectively (asterisks indicate statistical
significance). Error bars represent the
SEM of relative expression levels. The two
control samples used were from healthy
individuals with no known biochemical
or neurological phenotypes.
(B) Immunoblot analysis of MMACHC.
Fibroblast lysates from a reference (con-
trol) sample (human dermal fibroblast
C-013-5C, Life Technologies), two individ-
uals with cblX, and one with cblC were
analyzed. The cblX (lanes 2 and 3) and
cblC (lane 4) lines show only trace
amounts of MMACHC (top panel).
(C) Immunoblot analysis of HCFC1.
Fibroblast lysates from the same control
used in (B) and two cblX cell lines were
analyzed. HCFC1 levels in all the samples
remained unchanged. b-actin was used as
a loading control in all immunoblots (in
the bottom of B and C).
Figure 4. siRNA Knockdown of HCFC1
HEK293 cells were transfected with HCFC1-specific siRNA or
scrambled siRNA (control), and the relative expression of HCFC1
and MMACHC was assayed by qPCR using ACTB (b-actin) as an
endogenous control. Compared to control cells (average expres-
sion levels were fixed at 1), siRNA-treated cells had significantly
reduced HCFC1 (0.275) and MMACHC (0.424) expression levels,
but the MMADHC expression level remain unchanged. Error bars
represent the SEM of relative expression levels.The discovery of mutations in HCFC1 as the cause of the
cblX disorder highlights perturbation of transcription as
the cause of a classical inborn error of metabolism.
Although cblC and cblX share some clinical features, cblX
individuals were not documented to have the specific
bulls-eye maculopathy, which is a frequent finding in
cblC.5 Furthermore, the neurological features were more
severe (e.g., brain malformation, infantile spasms, move-
ment disorders) in cblX individuals, suggesting that
MMACHC deficiency alone does not explain all of the
clinical manifestations. The pathophysiology underlying
the complex phenotype remains to be fully elucidated
but most likely involves dysregulation of other HCFC1 tar-
gets. The recent discovery of variants in the regulatory
regions of HCFC1 as a possible cause of nonsyndromic
intellectual disability has implicatedHCFC1 in brain devel-
opment and function23 and, together with the data pre-
sented here, suggests that the metabolic manifestations
of MMACHC deficiency, along with mutation analysis of
HCFC1, should be assessed in individuals with idiopathic
X-linked intellectual disability.
We conclude that missense mutations affecting the
kelch domain of HCFC1 lead to combined methylmalonic
acidemia and hyperhomocysteinemia, establishing a
functional relationship between HCFC1 and cobalamin
metabolism. This distinct disorder establishes locus hetero-
geneity for cblC deficiency, most likely mediated by the
transcriptional regulation of genes involved in cobalamin
metabolism by HCFC1, and demonstrates that an inborn
error of metabolism can be caused by transcriptional
dysregulation.512 The American Journal of Human Genetics 93, 506–514, SeptembSupplemental Data
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